GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
    • Scientific Advisory Board
    • Reports
      • GHTM
  • Research
    • Cross-cutting issues
      • Antimicrobial Resistance and Drug Discovery
      • Host–Pathogen Interactions
      • Genomic Surveillance and Population Mobility
      • Implementation and Translational Research
      • Information for Health Development
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • PRIME – Pathogen resistance, infection and molecular epidemiology
      • VBD – Vector borne diseases
      • CTM – Clinical tropical medicine
    • Research in numbers
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
    • BIOHUB & Available Software
    • BIOTROP Biobank
    • VIASEF & Insectaries
  • Networks & Partnerships
Home / Archives for Theys K

Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

  • Authors: Abecasis A, Cabanas J, Camacho RJ, Gomes P, Libin P, Theys K, Van Laethem K
  • Publication Year: 2015
  • Journal: Journal of Clinical Virology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/26305833

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolutegravir activity after raltegravir use, and identified individual mutational patterns for which uncertainty […]
Read More

Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine

  • Authors: Camacho RJ, Gomes P, Portuguese HIVRSG, Rhee SY, Theys K, Vandamme AM
  • Publication Year: 2015
  • Journal: Clinical Microbiology and Infection
  • Link: http://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(15)00299-2/fulltext%20

Rilpivirine is a second-generation nonnucleoside reverse-transcriptase inhibitor (NNRTI) currently indicated for first-line therapy, but its clinical benefit for HIV-1 infected patients failing first-generation NNRTIs is largely undefined. This study quantified the extent of genotypic rilpivirine resistance in viral isolates from 1212 patients upon failure of efavirenz- or nevirapine-containing antiretroviral treatment, of whom more than respectively […]
Read More

A new ensemble coevolution system for detecting HIV-1 protein coevolution

  • Authors: Eusebio M, Khouri R, Li G, Piampongsant S, Pineda-Peña AC, Ramon J, Theys K, Vandamme AM, Verheyen J
  • Publication Year: 2015
  • Journal: Biology Direct
  • Link: https://biologydirect.biomedcentral.com/articles/10.1186/s13062-014-0031-8

A key challenge in the field of HIV-1 protein evolution is the identification of coevolving amino acids at the molecular level. In the past decades, many sequence-based methods have been designed to detect position-specific coevolution within and between different proteins. However, an ensemble coevolution system that integrates different methods to improve the detection of HIV-1 […]
Read More

An integrated map of HIV genome-wide variation from a population perspective

  • Authors: Faria NR, Khouri R, Lemey P, Li G, Piampongsant S, Pineda-Peña AC, Theys K, Vandamme AM, Voet A
  • Publication Year: 2015
  • Journal: Retrovirology
  • Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358901/

Background: The HIV pandemic is characterized by extensive genetic variability, which has challenged the development of HIV drugs and vaccines. Although HIV genomes have been classified into different types, groups, subtypes and recombinants, a comprehensive study that maps HIV genome-wide diversity at the population level is still lacking to date. This study aims to characterize […]
Read More

Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase

  • Authors: Bernatchez J, Camacho RJ, Covens K, De Wit S, Dekeersmaeker N, Götte M, Megens S, Theys K, Van Laethem K, Vandamme AM, Vinken L
  • Publication Year: 2014
  • Journal: Acta Clinica Belgica
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25103592

The amino acid position 70 in HIV-1 reverse transcriptase (RT) plays an important role in nucleoside RT inhibitor (NRTI) resistance. K70R is part of the thymidine analog mutations, but also other amino acid changes have been associated with NRTI resistance, such as K70E and K70G. In this study, we investigated the in vivo selection of the HIV-1 RT mutations K70S and K70T and their in vitro effect on drug resistance and replication capacity.
Read More

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Funding

UID/04413/2025 - DOI: 10.54499/UID/04413/2025

UID/PRR/04413/2025 - DOI: 10.54499/UID/PRR/04413/2025

UID/PRR2/04413/2025 - DOI: 10.54499/UID/PRR2/04413/2025

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2026 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.